Mycenax Signs an Agreement with Gedeon Richter for LusiNEX
Shots:
- Mycenax to sell LusiNEX project- including cell banks- CMC technology- intellectual properties- and clinical trial results to Gedeon Richter making a total deal value $16.5M. Mycenax to get payments as it completes the stages of asset transfer which will be utilized to operation and facility expansion which further strengthen Mycenax’s capacities in CDMO business
- The focus of the agreement is to fully focus on its CDMO business and become one of the CDMO companies in Asia
- LusiNEX is a biosimilar product of Actemra/ RoActemra and has completed its P-I demonstrating bioequivalence in 2018 and is expected to enter in P-III trial while further receiving market approval
Click here to read full press release/ article | Ref: Mycenax | Image: Pharmaworld
Tags
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com
